Sector News

Reuters: Apollo to bid for GlaxoSmithKline’s mature drugs

November 14, 2014
Life sciences
(Reuters) – Apollo Global Management is planning to bid for all GlaxoSmithKline’s mature drugs, joining an auction expected to value the business at more than $3 billion (1.19 billion pounds), according to four people familiar with the process.
 
The private equity firm, run by Leon Black, could change the dynamic of the auction because it is ready to buy all the products on offer, while other potential buyers are looking to acquire only certain regional businesses.
 
Apollo, GSK declined to comment.
 
BY SOPHIE SASSARD AND FREYA BERRY (Editing by Alex Smith)
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach